You are here
The Award database is continually updated throughout the year. As a result, data for FY23 is not expected to be complete until September, 2024.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
SBC: POINT DESIGNS, LLC Topic: NICHD
The Point DigitA Ratcheting Prosthetic Finger UsingAdvanced Rapid Manufacturing Technology Project SummaryAbstract The goal of the proposed project is to develop and commercialize a purely mechanicalratcheting prosthetic fingerthe Point Digitwhichhas an industry leading strength to weight ratiocan be operated unilaterallyone handedoffers anatomical rotation and flexion around the patient s metacar ...STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
SBC: Applied Universal Dynamics, Corp. Topic: 107
PROJECT SUMMARY This proposal responds to PAR-18-870 titled “BRAIN Initiative: Development Optimization, and Validation of Novel Tools and Technologies for Neuroscience Research (STTR).” This project is a Fast Track STTR with a phase I and phase II. The small business, Applied Universal Dynamics Corp. (AUD) is collaborating with the University of Minnesota (U of MN). The activity patterns of t ...STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
SBC: VIROGENOMICS BIODEVELOPMENT INC Topic: R41
Methamphetamine use disorder is associated with damage to regions of the brain that control cognitive and psychiatric functionOne third to one half of adults with methamphetamine use disorder experience cognitive impairments and other psychiatric symptoms that significantly impact treatment outcomesincreased relapse and lower treatment retention ratesMounting evidence demonstrates how immune facto ...STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
SBC: LEXEO Therapeutics LLC Topic: 400
AbstractLEXEO TherapeuticsLLCis an early stage biotechnology company focused on using in vivo gene therapy technologies to treat disorders of unmet medical needLEXEO is developing an in vivo gene therapy strategy as a preventative therapy to protect individuals with aldehyde dehydrogenaseALDHdeficiency from the high risk for esophageal cancerAs the next step in the development paththe goal of this ...STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
SBC: BEAM Diagnostics, Inc. Topic: 41
PROJECT SUMMARY Fatal overdose from opioid misuse is one of the most pressing issues affecting the modern worldAs one of the nation s leading preventable causes of deatha critical line of defense against opioid use disorderOUDmust be standardized screening provided by the patient s primary care physicianpsychiatristand or counselorStandardized screening methods for opioidshoweverare simply inferio ...STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
SBC: BIOMIMETIX JV LLC Topic: 102
Ischemic stroke is a leading cause of death and disability in the United States. This often is attributable to thrombus formation at an atherosclerotic plaque or thromboembolism. Patients who present within 4.5 hours of symptom onset are eligible for thrombolysis with tissue plasminogen activator (tPA). This serves andlt;5% of victims. Recently, major advance has been made with proven efficacy fro ...STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
SBC: Vova Ida, LLC Topic: 999
SUMMARYParkinsonandapos s diseasePDis the second most prevalent neurodegenerative disorder after Alzheimerandapos s diseaseADaffecting more thanmillion people in the United StatesBecause age is the major risk factorthe prevalence of both diseases is steadily increasing as our population agesPD belongs to the group of protein misfolding neurodegenerative diseases that are due to the misfolding and ...STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
SBC: VASCULAR VISION PHARMACEUTICAL CO Topic: NHLBI
AbstractThe pathogenesis of Sickle cell diseaseSCDcomprises a complex interplay of factors associated with vascular endothelial activationintense inflammationand increased sickle cell adhesionMicrovascular occlusion in SCD is initiated by adhesion of sickle red blood cellsRBCsto the endotheliumleading to acute painful vasoocclusive crisisVOCand the clinical morbidity in SCDTreatment strategies inc ...STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
SBC: LEXEO Therapeutics LLC Topic: NHLBI
AbstractThe focus of this proposal is the development of therapy to protect the lung with an extracellular anti oxidant defense to treat chronic obstructive pulmonary diseaseCOPDa chronic disorder in which inhaled oxidants from tobacco smokepollution and generated within the lung by activated inflammatory cells perpetuate injury to the lung epithelium and endotheliumThe LEXEO strategy is to use in ...STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
SBC: Simulated Inanimate Models LLC Topic: 103
Project SummarySimulation training is unique in its ability for repetitive practice of a wide variety of scenarios and to reflect on performance without jeopardizing a patient s safetySurgical skills simulators have been successful in bridging gaps of the current training modelhoweverthese simulators fall short of offering a complete operative experienceOperative exposure with live patients still ...STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health